ArticleAccounts of chemical research2012
Charge-reversal lipids, peptide-based lipids, and nucleoside-based lipids for gene delivery.
Article in Accounts of chemical research, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 66 citations in OpenAlex.
- Self-Assembling Cationic Lipopeptides for the Construction of Functional Vesicular Gene-Delivery Systems.Small (Weinheim an der Bergstrasse, Germany) · 2026Article
- Liposome-mediated gene delivery: A comprehensive review of biophysical parameters, lipid composition and targeting strategies.ADMET & DMPK · 2026Review
- Boron clusters as broadband membrane carriers.Nature · 2022Article
- Carbodiimide-Driven Dimerization and Self-Assembly of Artificial, Ribose-Based Amphiphiles.Chemistry (Weinheim an der Bergstrasse, Germany) · 2022Article
- Rational preparation and application of a mRNA delivery system with cytidinyl/cationic lipid.Journal of controlled release : official journal of the Controlled Release Society · 2021Article
- Charge-Conversion Strategies for Nucleic Acid Delivery.Advanced functional materials · 2021Article
- From Interaction to Function in DNA-Templated Supramolecular Self-Assemblies.ChemistryOpen · 2020Review
- Biodegradable Gene Carriers Containing Rigid Aromatic Linkage with Enhanced DNA Binding and Cell Uptake.Polymers · 2018Article
- Transfection by cationic gemini lipids and surfactants.MedChemComm · 2018Review
- Skeleton-Controlled pDNA Delivery of Renewable Steroid-Based Cationic Lipids, the Endocytosis Pathway Analysis and Intracellular Localization.International journal of molecular sciences · 2018Article
- Engineering liposomal nanoparticles for targeted gene therapy.Gene therapy · 2017Review
- Spermine-modified Antheraea pernyi silk fibroin as a gene delivery carrier.International journal of nanomedicine · 2016Article
- Tri-peptide cationic lipids for gene delivery.Journal of materials chemistry. B · 2015Article
- Designer lipids for drug delivery: from heads to tails.Journal of controlled release : official journal of the Controlled Release Society · 2014Review
- Complex self-assembly of pyrimido[4,5-d]pyrimidine nucleoside supramolecular structures.Nature communications · 2014Article
- Lipid-mediated DNA and siRNA Transfection Efficiency Depends on Peptide Headgroup.Soft matter · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
Abstract
Twenty years after gene therapy was introduced in the clinic, advances in the technique continue to garner headlines as successes pique the interest of clinicians, researchers, and the public. Gene therapy's appeal stems from its potential to revolutionize modern medical therapeutics by offering solutions to myriad diseases through treatments tailored to a specific individual's genetic code. Both viral and non-viral vectors have been used in the clinic, but the low transfection efficiencies when non-viral vectors are used have lead to an increased focus on engineering new gene delivery vectors. To address the challenges facing non-viral or synthetic vectors, specifically lipid-based carriers, we have focused on three main themes throughout our research: (1) The release of the nucleic acid from the carrier will increase gene transfection. (2) The use of biologically inspired designs, such as DNA binding proteins, to create lipids with peptide-based headgroups will improve delivery. (3) Mimicking the natural binding patterns observed within DNA, by using lipids having a nucleoside headgroup, will produce unique supramolecular assembles with high transfection efficiencies. The results presented in this Account demonstrate that engineering the chemical components of the lipid vectors to enhance nucleic acid binding and release kinetics can improve the cellular uptake and transfection efficacy of nucleic acids. Specifically, our research has shown that the incorporation of a charge-reversal moiety to initiate a shift of the lipid from positive to negative net charge improves transfection. In addition, by varying the composition of the spacer (rigid, flexible, short, long, or aromatic) between the cationic headgroup and the hydrophobic chains, we can tailor lipids to interact with different nucleic acids (DNA, RNA, siRNA) and accordingly affect delivery, uptake outcomes, and transfection efficiency. The introduction of a peptide headgroup into the lipid provides a mechanism to affect the binding of the lipid to the nucleic acid, to influence the supramolecular lipoplex structure, and to enhance gene transfection activity. Lastly, we discuss the in vitro successes that we have had when using lipids possessing a nucleoside headgroup to create unique self-assembled structures and to deliver DNA to cells. In this Account, we state our hypotheses and design elements as well as describe the techniques that we have used in our research to provide readers with the tools to characterize and engineer new vectors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.